CD37 and B-cell non-Hodgkin lymphoma: Preclinical data from multiple B cell lymphoma cell lines have demonstrated a synergistic cytotoxic effect of an anti-CD37 naratuximab emtansine combined with anti-CD20 mAbs (rituximab, ofatumumab, and obinutuzumab) [83].